Challenges, Shared Decision Making and Health Equity in Hemophilia and a rebalancing approach with HYMPAVZI (marstacimab-hncq)

Friday, March 21, 1:00pm - 2:00pm (EDT)

Time shown in-04:00 America, New York

To educate attendees on the novel mechanism of action of HYMPAVZI, the BASIS Ph3 clinical trial results and dosage and administration of HYMPAVZI.

__________

*HYMPAVZI is a TFPI antagonist.
Hympavzi is a trademark of Pfizer Inc.

Add to Calendar 2025/03/21 13:00:00 2025/03/21 14:00:00 America/New_York Challenges, Shared Decision Making and Health Equity in Hemophilia and a rebalancing approach with HYMPAVZI (marstacimab-hncq)

To educate attendees on the novel mechanism of action of HYMPAVZI, the BASIS Ph3 clinical trial results and dosage and administration of HYMPAVZI.

__________

*HYMPAVZI is a TFPI antagonist.
Hympavzi is a trademark of Pfizer Inc. https://www.pfizerhemophiliawebinars.com/ false MM/DD/YYYY 30 OPAQUE avZuWStRUzjHnaTENmGz88174

https://www.pfizerhemophiliawebinars.com/